<DOC>
	<DOCNO>NCT01499420</DOCNO>
	<brief_summary>Reconstituted high density lipoprotein use patient acute coronary syndrome ( ACS ) may reduce atherosclerotic plaque burden , thereby reduce risk recurrent cardiovascular event . This study multi-center , randomize , placebo-controlled , single ascend dose study patient stable atherothrombotic disease safety pharmacokinetic profile CSL112 assess .</brief_summary>
	<brief_title>A Single Ascending Dose Study Examining Safety Pharmacokinetic Profile Reconstituted High Density Lipoprotein ( CSL112 ) Administered Patients</brief_title>
	<detailed_description />
	<criteria>Male female age 18 year 80 year . Subjects must document evidence history atherosclerotic coronary artery disease/surgical revascularization . Subjects stable medication regimen . Body weight 50 kg great screen . Moderate/severe heart failure renal impairment . Uncontrolled hyperglycemia subject type 1 type 2 diabetes . Receipt combination omeprazole clopidogrel within 1 month randomization . Subjects whose medical history , condition medication regimen may interfere evaluation safety tolerability CSL112 ( example significantly alter electrocardiogram ( ECG ) waveform , hepatobiliary disease , malignancy , thrombocytopenia , etc . ) Known hypersensitivity product component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>